Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02317549
NCT02317549TerminatedPhase 2

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148 (SSAIL Trial)

Leading BioSciences, Inc34 sites in 2 countries8 target enrollmentStarted: April 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Terminated
Enrollment
8
Locations
34
Primary Endpoint
Number of Days Alive Without Cardiovascular, Renal or Pulmonary Organ Support
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Septic shock is a potentially life-threatening condition that can result in multi-organ dysfunction syndrome (MODS) and mortality. LB1148 was formulated to preserve gut integrity during physiological shock and ameliorate the subsequent autodigestion leading to MODS and mortality. The purpose of this study in septic shock patients is to determine if enteral administration of LB1148 will increase the number of days alive without cardiovascular, pulmonary or renal replacement therapy through Day 28.

Detailed Description

Primary Objective(s):

The primary objective of this study is to determine if enteral administration of LB1148 will increase the number of days alive without cardiovascular, renal or pulmonary organ support through Day 28.

The secondary objectives of this study are to determine if LB1148 will:

  • Reduce mortality at Day 7, Day 28 and Day 90;
  • Reduce the number of days to organ dysfunction resolution as evidenced by Sequential Organ Failure Assessment (SOFA) score ≤2 in patients alive on Day 28;
  • Reduce the daily organ dysfunction as evidenced by average SOFA score through Day 14 and Day 28;
  • Reduce the number of patients with new-onset organ dysfunction at Day 8;
  • Increase the number of days alive and free from renal replacement therapy through Day 28;
  • Increase the number of days alive and free from renal dysfunction through Day 28;
  • Increase the number of days alive and ventilator free through Day 28;
  • Increase the number of days alive and free of vasopressors through Day 14 and Day 28;
  • Increase the numbers of days alive and free from liver dysfunction through Day 28;
  • Increase the number of days alive and not in the Intensive Care Unit (ICU) through Day 28;
  • Increase the number of days alive and not in the hospital through Day 28, and
  • Improve patient functional outcomes through Day 28 as evidenced by the EuroQoL EQ 5D questionnaire.

In addition, the study will assess the safety and tolerability of LB1148 in patients with septic shock.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •First episode (during the current hospitalization) of documented or suspected sepsis of peritoneum/abdomen, soft tissue, blood, or non-hospital acquired lung origin.
  • •Must be receiving antimicrobial therapy for documented or suspected infection.
  • •Must have septic shock requiring vasopressors despite adequate fluid resuscitation of 30 mL/kg crystalloid or colloid equivalent, for either an SBP ≤90 mmHg or a MAP ≤65 mmHg (i.e. must have been unable to maintain adequate blood pressure despite adequate fluid resuscitation without the use of vasopressors). Note: 30 mL/kg crystalloid is equivalent to 15 mL/kg colloids.
  • •Must have a requirement for vasopressor support after adequate fluid resuscitation, and, at randomization, must require a minimum dose of at least 1 of the following vasopressors:
  • •Norepinephrine ≥5 µg/min;
  • •Dopamine ≥10 µg/kg/min;
  • •Phenylephrine ≥25 µg/min;
  • •Epinephrine ≥5 µg/min, or
  • •Vasopressin ≥0.03 units/min.
  • •Exclusion Criteria
  • •Patients will not be eligible for participation in the study if they meet ANY of the following criteria:
  • •Age <18 or age ≥76 years.
  • •Time elapsed since onset of shock is >24 hours. Onset of shock is defined as the first administration of a vasopressor given by continuous infusion (i.e. not a single bolus of norepinephrine, phenylephrine, or ephedrine).
  • •Septic shock episode is the second or greater episode in current hospitalization.
  • •Note: patients transferred from another healthcare facility that are still within the first 24 hours of the first episode of shock are eligible.
  • •Have hospital acquired pneumonia.
  • •Have genitourinary infections as the cause of septic shock.
  • •Unable to maintain a minimum MAP of 60 mmHg despite the presence of vasopressors and IV fluids.
  • •Note: brief transient BPs below 60 mmHg are not disqualifying.
  • •Have a serum lactate measurement <2.5 mmol/L after adequate fluid resuscitation (refer to Inclusion Criteria #3).
  • •Not expected to survive for at least 28 days due to a preexisting, non-shock related medical condition.
  • •Highest total SOFA score (known to staff at the time of randomization) during the screening period <
  • •Note: each individual organ component sub-score is calculated from the highest (worst) score obtained for that organ during the screening period, up until randomization.
  • •Highest total SOFA score (known to staff at the time of randomization) during the screening period >
  • •Note: each individual organ component sub-score is calculated from the highest (worst) score obtained for that organ during the screening period.
  • •Lack of commitment to aggressive source control of infection.
  • •The patient or patient's surrogate fails to voluntarily sign an informed consent form (ICF).
  • •Ineligible for feeding tube placement.
  • •Chronic renal insufficiency requiring hemodialysis not associated with the current episode of sepsis.
  • •Chronic pulmonary dysfunction requiring mechanical ventilation unrelated to the current episode of sepsis.
  • •Undergoing active radiation or cytotoxic chemotherapy treatment for uncontrolled malignancy.
  • •Note: hormonal and surgical therapies are permitted.
  • •Presence of third degree burns involving >20% body surface area in the 7 days prior to study entry.
  • •Known inability to take the study medication (i.e. complete small bowel obstruction).
  • •Has acute meningitis.
  • •Have any of the following medical conditions:
  • •HIV-positive patients whose most recent CD4 count was ≤50/mm3;
  • •Neutrophils <1000/mm3 unless due to sepsis;
  • •Received chest compressions as part of CPR during this hospitalization without neurologic recovery;
  • •Poorly controlled neoplasm;
  • •End-stage lung disease or Cystic Fibrosis;
  • •End-stage liver disease (Child-Pugh Class C [score >10], evidence of portal hypertension or esophageal varices);
  • •Severe congestive heart failure (New York Heart Association [NYHA] Class IV or pre-sepsis ejection fraction <30%);
  • •Undergone organ transplant (including bone marrow, heart, lung, liver, pancreas, or small bowel transplantation), or
  • •Primary ICU admitting diagnosis of acute myocardial infarction (MI).
  • •Have relative contraindications to taking TXA or have a believed adverse risk/benefit ratio for taking the drug. These include patients with:
  • •Known sensitivity to TXA;
  • •Recent craniotomy (past 28 days);
  • •Active cerebrovascular bleed;
  • •Active thromboembolic disease, (such as deep vein thrombosis, pulmonary embolism [PE], cerebral thrombosis, ischemic stroke, or acute coronary syndrome [ACS]);
  • +7 more not shown

Exclusion Criteria

  • Not provided

Arms & Interventions

Tranexemic Acid

Experimental

Daily a total of 700 mL of LB1148 solution containing 7.5 g of tranexemic acid will be administered orally or via NG/OG/NJ/ND/PEG tube

Intervention: LB1148 (Drug)

Placebo

Placebo Comparator

Daily a total of 700 mL of Placebo solution will be administered orally or via NG/OG/NJ/ND/PEG tube

Intervention: Placebo (Drug)

Outcomes

Primary Outcomes

Number of Days Alive Without Cardiovascular, Renal or Pulmonary Organ Support

Time Frame: Through day 28.

The patient will be classified as having organ support if organ support is required through the use of: * Mechanical ventilation; * Vasopressors to maintain adequate blood pressure (BP), or * Renal replacement therapy.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (34)

Loading locations...

Similar Trials

Completed
Phase 3
ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO)Septic Shock Hyperdynamic
NCT03788837Assistance Publique - Hôpitaux de Paris240
Not yet recruiting
Not Applicable
Effect of Nutritional Support and Early Rehabilitation on SepsisLife QualityHospital Mortality
NCT05781971Jinling Hospital, China1,600
Completed
Phase 1
Effects of Endotoxin in Normal Human VolunteersHealthyLung DiseaseSepsisSeptic Shock
NCT00001303National Institutes of Health Clinical Center (CC)198
Unknown
Phase 2
Cellular Immunotherapy for Septic ShockPathologic ProcessesShockInfectionSepsisSeptic ShockInflammationSystemic Inflammatory Response Syndrome
NCT03369275Ottawa Hospital Research Institute114
Unknown
Not Applicable
The Effect and Mechanism of lncRNA NBR2 Regulating Endothelial Pyroptosis by Targeting GSDMD in SepsisSepsis
NCT04427371Jianfeng Xie100
Treatment of Septic Shock by Inhibiting... | Clinical Trial